Aliskiren, an Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Sustained 24-Hour Blood Pressure Control in Patients With Hypertension

Journal of the American College of Cardiology

Volumn 49, Issue 11, 2007, Pages 1157-1163

  Oh, Byung Hee ^a   Mitchell, Jerry ^b,c   Herron, James R ^d   Chung, Jenny ^e   Khan, Mahmudul ^e   Keefe, Deborah L ^e  

^a Seoul National University Hospital   (South Korea)

^b Texas Center for Drug Development   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MD Ltd   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; PLACEBO; RENIN INHIBITOR;

ADULT; ARTICLE; BACKACHE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VEIN OCCLUSION;

ADMINISTRATION, ORAL; AGED; AMIDES; BLOOD PRESSURE DETERMINATION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FUMARATES; HUMANS; HYPERTENSION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; REFERENCE VALUES; RENIN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33947182655     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.11.032     Document Type: Article

References (26)

1. Wood J.M., Maibaum J., Rahuel J., et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308 (2003) 698-705
2. Vaidyanathan S., Limoges D., Yeh C.-M., and Dieterich H.-A. Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 79 (2006) P64 (abstr)
3. Vaidyanathan S., Zhao C., Yeh C.-M., and Dieterich H.A. Pharmacokinetics and safety of the novel oral renin inhibitor aliskiren in patients with type 2 diabetes. Clin Pharmacol Ther 79 (2006) P12 (abstr)
4. Meredith P.A. Organ protection and optimal blood pressure control. Am J Hypertens 8 (1995) 59S-62S
5. Myers M.G. Twenty-four-hour blood pressure control: a brief review of aspects of target-organ protection. J Hypertens Suppl 14 (1996) S7-S10
6. Frattola A., Parati G., Cuspidi C., Albini F., and Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens 11 (1993) 1133-1137
7. Gradman A.H., Schmieder R.E., Lins R.L., Nussberger J., Chiang Y., and Bedigian M.P. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111 (2005) 1012-1018
8. Stanton A., Jensen C., Nussberger J., and O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42 (2003) 1137-1143
9. Nussberger J., Wuerzner G., Jensen C., and Brunner H.R. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 39 (2002) E1-E8
10. Nussberger J., Gradman A.H., Schmieder R.E., et al. Changes in plasma renin match the antihypertensive effects of aliskiren in patients with hypertension: placebo/irbesartan-controlled trial with the orally active renin inhibitor aliskiren. Am J Hypertens 18 (2005) 234A
11. AHA Committee. American Heart Association Committee report on blood pressure determination. Hypertension 11 (1988) 210A-222A
12. Dunnett C.W. Pairwise multiple comparisons in the homogeneous variances, unequal sample size case. J Am Stat Assoc 75 (1980) 796-800
13. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50 (1955) 1096-1121
14. Azizi M., Webb R., Nussberger J., and Hollenberg N.K. Renin inhibition with aliskiren: where are we now, and where are we going?. J Hypertens 24 (2006) 243-256
15. Elmfeldt D., Olofsson B., and Meredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press 11 (2002) 293-301
16. Lewington S., Clarke R., Qizilbash N., Peto R., and Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
17. Preston R.A., Materson B.J., Reda D.J., et al., Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA 280 (1998) 1168-1172
18. Bakris G.L., Smith D.H., Giles T.D., White W.B., Davidai G., and Weber M.A. Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients. J Clin Hypertens (Greenwich) 7 (2005) 587-595
19. Veerman D.P., de Blok K., and van Montfrans A. Relationship of steady state and ambulatory blood pressure variability to left ventricular mass and urinary albumin excretion in essential hypertension. Am J Hypertens 9 (1996) 455-460
20. Millar-Craig M.W., Bishop C.N., and Raftery E.B. Circadian variation of blood-pressure. Lancet 1 (1978) 795-797
21. Muller J.E., Stone P.H., Turi Z.G., et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 313 (1985) 1315-1322
22. Willich S.N., Levy D., Rocco M.B., Tofler G.H., Stone P.H., and Muller J.E. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 60 (1987) 801-806
23. Zannad F., Matzinger A., and Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 9 (1996) 633-643
24. Azizi M., Menard J., Bissery A., et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 15 (2004) 3126-3133
25. Vaur L., Bobrie G., Dutrey-Dupagne C., et al. Short-term effects of withdrawing angiotensin converting enzyme inhibitor therapy on home self-measured blood pressure in hypertensive patients. Am J Hypertens 11 (1998) 165-173
26. Cleophas T.J., van Ouwerkerk B.M., van der Meulen J., and Zwinderman A.H. Diabetics with hypertension not controlled with ACE inhibitors: alternate therapies. Angiology 52 (2001) 469-475